TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology. This…
| Price | $4.91 |
|---|---|
| Market cap | $302.35M |
| Sector | Healthcare |
| Industry | Medical - Devices |
| Exchange | NASDAQ |
| 52-week range | 2.2-7.95 |
| Beta | 0.44 |
Explore TLSI's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.